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Abstract
Background: A major change has occurred in the last few years in the therapeutic approach to
patients presenting with all forms of acute coronary syndromes. Whether or not these patients
present initially to tertiary cardiac care centers, they are now routinely referred for early coronary
angiography and increasingly undergo percutaneous revascularization. This practice is driven
primarily by the angiographic image and technical feasibility. Concomitantly, there has been a
decline in expectant or ischemia-guided medical management based on specific clinical
presentation, response to initial treatment, and results of noninvasive stratification. This
'tertiarization' of acute coronary care has been fuelled by the increasing sophistication of the
cardiac armamentarium, the peer-reviewed publication of clinical studies purporting to show the
superiority of invasive cardiac interventions, and predominantly supporting (non-peer-reviewed)
editorials, newsletters, and opinion pieces.
Discussion: This review presents another perspective, based on a critical reexamination of the
evidence. The topics addressed are: reperfusion treatment of ST-elevation myocardial infarction;
the indications for invasive intervention following thrombolysis; the role of invasive management in
non-ST-elevation myocardial infarction and unstable angina; and cost-effectiveness and real world
considerations. A few cases encountered in recent practice in community and tertiary hospitals are
presented for illustrative purposes The numerous and far-reaching scientific, economic, and
philosophical implications that are a consequence of this marked change in clinical practice as well
as healthcare, decisional and conflict of interest issues are explored.
Summary: The weight of evidence does not support the contemporary unfocused broad use of
invasive interventional procedures across the spectrum of acute coronary clinical presentations.
Excessive and unselective recourse to these procedures has deleterious implications for the
organization of cardiac health care and undesirable economic, scientific and intellectual
consequences. It is suggested that there is need for a new equilibrium based on more refined clinical
risk stratification in the treatment of patients who present with acute coronary syndromes.
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Background
Over the past few years, a major change has occurred in
the approach to patients presenting with acute coronary
syndromes (ACS), from predominantly expectant medical
management, based on specific clinical presentation,
response to initial treatment, evolution, and results of
noninvasive risk stratification, towards rapid and increas-
ingly systematic coronary angiography. This change has
paved the way to percutaneous coronary revascularization
(PCI), largely driven by angiographically perceived coro-
nary anatomy and technical feasibility. Clinical success
tends to be measured in terms of the physician's satisfac-
tion with the immediate angiographic result of the inter-
vention, ever easier and safer to assure because of the
improving skills of interventional cardiologists and the
increasing sophistication of the cardiac armamentarium.
Tertiary hospitals and interventional cardiologists are
understandably eager to extend these services to commu-
nity and regional hospitals, since, beyond the conviction
that this is the best approach, this also reinforces their rai-
son d'être, justifying claims for more new high-tech
resources and, depending on the socioeconomic environ-
ment, potentially increasing revenues. Trainees in tertiary
academic centers are becoming conditioned to the 'culture
of intervention' as the natural way to practice cardiology.
Clinicians in non-tertiary centers increasingly refer their
patients for invasive management so as not to deprive
them of this new standard of care. While progress in the
field of interventional cardiology has undoubtedly had a
beneficial impact on the ability to manage acute coronary
disease, the skeptic may be struck by how an invasive car-
diac approach has become the norm, predicated less on
clear clinical need and increasingly on the presumption
that this is the best thing to do, the technological impera-
tive. In the design and interpretation of clinical trials, and
in reviews, opinion pieces, and editorials, the contempo-
rary medical literature has predominantly supported,
indeed reinforced, this tendency [1-5]. We believe there is
need for another perspective. This article, using typical
cases culled from our routine practice, examines the evi-
dence on which the current invasive approach to ACS is
based, and explores its far-reaching clinical, economic,
and intellectual implications.
Discussion
Choice of initial reperfusion therapy in ST-elevation 
myocardial infarction (STEMI)
Case 1
A 75-year-old woman presented at a regional hospital with a 2-
hour history of increasing chest discomfort. The electrocardio-
gram (ECG)showed 3-mm ST-segment elevation in inferior
leads. The patient was given aspirin and heparin and trans-
ferred 30 miles by ambulance to a tertiary center for primary
angioplasty. Coronary angiography was begun 2.5 hours later
and showed single-vessel disease, a 70% right coronary artery
ostial stenosis with TIMI-3 flow. Angioplasty was performed
with insertion of three stents with an intravenous infusion of
the platelet glycoprotein IIb/IIIa blocker, abciximab. The
patient was re-transferred the next day and recovered unevent-
fully.
This case raises the issues of unseemly treatment delays on
outcomes and the rationale for intervention when appar-
ent reperfusion (TIMI-3 flow) has occurred.
The widely accepted notion that primary angioplasty (PA)
is superior to thrombolysis is based on the recent meta-
analysis of 23 randomized trials by Keeley et al showing a
2% mortality advantage for angioplasty (7% versus 9%, p
= 0.0002) [6]. However, the overall conclusion of this
meta-analysis may be questioned as older trials, using less
efficient thrombolytic strategies, and one large trial
(SHOCK) not comparing thrombolysis to PA were
included. Thus, when the 11 trials using rapidly adminis-
tered, but not bolus, fibrin-specific agents are considered
separately, a significant advantage for angioplasty is either
modestly present (p = 0.018) [6] or no longer so (1.1 lives
saved/100 patients treated, 95% CI [minus]0.3/100 to
2.6/100) [7], depending on the analytical methods. When
statistical significance hinges on model assumptions, it
suggests that evidence of superiority for any reperfusion
approach is fragile.
Time is a critical determinant of survival with any reper-
fusion strategy [8,9]. Each hour of delay to thrombolysis
is associated with a loss of at least 1.6 lives/100 treated,
and possibly many more if the 'golden' first hour after
symptom onset is missed [10,11]. Concordant with these
observations, prehospital thrombolysis with a 58-minute
reduction in treatment time has been shown to confer a
1.7% absolute reduction in mortality compared with in-
hospital thrombolysis [8]. A meta regression analysis
from the 23 thrombolysis/PA trials has shown loss of the
survival benefit for angioplasty when 'door-to-balloon'
time exceeds 'door-to-needle' time for thrombolysis by 60
minutes [12]. Very recent large registry data confirm sig-
nificant step-ups in mortality for each 30-minute increase
in door-to-balloon time beyond 90 minutes [13]. Thus, a
coherent body of knowledge underpins the importance of
time until treatment and its corollary that in certain situa-
tions thrombolysis may be just as effective, than PA, or
even more so. This corollary has been further underscored
by a recent trial demonstrating improved clinical out-
comes with prehospital thrombolysis and judicious
recourse to so-called rescue angioplasty compared with
PA [14,15].
Questions remain as to the practicality or applicability of
published results favorable to PA. The mean delay to bal-
loon inflation in the clinical trials was only 40 minutesBMC Medicine 2006, 4:25 http://www.biomedcentral.com/1741-7015/4/25
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but in the real world, delays are far longer and it is not
established that similar clinical results may be attained
[16-18]. Also, the mortality in the thrombolytic arms of
these studies was higher (8–14%) than that noted in con-
temporary registry and trial data of thrombolytic therapy
(5–6%) [17,19,20]. Outcomes with PA depend on vol-
ume of activity [16,21] and whether the procedure is per-
formed during or off normal working hours [22],
limitations that have not been shown to apply to throm-
bolysis [16]. While recently updated STEMI guidelines
[23] acknowledge that no single reperfusion strategy is
appropriate for all patients and emphasize that the timely
use of some reperfusion therapy is likely more important
than the choice of therapy, these judicious considerations
are not reflected in the current climate of enthusiasm with
interventional cardiology.
The other two outcomes regarding which PA is claimed to
be superior are strokes and myocardial reinfarctions.
While there are about three more incapacitating hemor-
rhagic strokes per 1000 in patients treated with thrombol-
ysis than in those treated with PA, there are about 20
excess major bleeds with angioplasty [6,24]. Bleeding can
be more than an inconvenience; it has very recently been
found to be independently associated with greater mortal-
ity in patients with ACS, both at 30 days and at 6 months.
[25] Quantification of reinfarction benefit is confounded
by ascertainment bias, differing cardiac enzyme criteria
depending on whether reinfarction is spontaneous or
PCI-related, unbalanced use of a second antiplatelet agent
(generally clopidogrel) that reduces reinfarction [26,27],
and the problematic consideration of ST-segment re-ele-
vation in the immediate hours following the initiation of
thrombolytic therapy. Although these latter events tend to
be counted as reinfarctions, the complications that are
mostly unique to primary PCI (no reflow, dissection, dis-
tal embolization, and side-branch occlusion) [28] and
that might be considered iatrogenic reinfarctions are not
systematically recorded in the trials. These limitations
underline the uncertainty regarding the pertinence of the
reinfarction end point in these comparative trials.
Thus, while a small benefit of PA over optimal fibrin-spe-
cific thrombolysis is suggested, uncertainty still clouds
this issue and both options remain acceptable. The addi-
tion of clopidogrel to thrombolysis is likely to improve
the performance of the latter relative to PA [26,27]. A
recent regression analysis based on the randomized clini-
cal trials suggests no benefit of PA over thrombolysis
when the mortality risk of STEMI is < 4.5% and possible
harm with treatment delay [29]. Therefore, discriminating
clinicians might reserve the recourse to PA for patients
with acute myocardial infarction (MI) at particular risk
(patients with heart failure or hemodynamic instability or
high bleeding risk from thrombolysis) [17,30,31]. The
importance of avoiding excessive delays with hospital
transfers and off-hours angioplasty that may compromise
patient outcomes compared with prompt on-site throm-
bolysis cannot be overemphasized. Is it not paradoxical
that PA is so highly promoted when it is in fact delivered
within the time frames recommended by evidence-based
guidelines in only a minority of cases [18]?
Plasticity of indications for PCI after thrombolysis
Case 2
Twenty-four hours after thrombolysis of a Q-wave inferior MI,
a 71-year old man had 5 minutes of mild chest discomfort fol-
lowed by spontaneous resolution. There were no associated
hemodynamic or dynamic electrocardiographic abnormalities
noted. An angiogram was ordered and performed the next day.
The patient had single-vessel disease with an occluded right cor-
onary artery that was successfully reopened with 2 stents
inserted under an infusion of eptifibatide, a platelet glycopro-
tein IIb/IIIa receptor blocker. There was normal TIMI-3 flow.
The contrast ventriculogram showed inferior akinesia with an
ejection fraction over 50%. The patient did well subsequently.
An echocardiogram a year later showed unchanged inferior aki-
nesia.
This case raises the issues of whether invasive intervention
is indicated for recurrent mild, self-limited symptoms fol-
lowing MI and whether delayed opening of an occluded
coronary artery after MI is beneficial, relative to the
expenses and risks, given our current understanding of
myocardial viability.
Even when the initial approach in STEMI is thrombolysis,
the threshold for invasive intervention is becoming ever
lower, more as a function of the improved safety of the
procedure than proof of improved outcomes. Another
common example is the patient sent for 'rescue' angi-
oplasty after thrombolysis because of residual chest pain,
despite ST-segment resolution. Persistent but diminishing
chest discomfort is common following presentation with
acute MI and we believe that it tends not to be distin-
guished from new or ongoing ischemia. Nor is it appreci-
ated how symptoms may be amplified by the attitude and
behavior of the treating team. The 'rescue' coronary angi-
ogram will undoubtedly reveal a culprit lesion that will be
stented even if flow is already satisfactory on angiographic
imaging, and frequently even if the stenosis is no longer
significant. The threshold for this intervention can be
expected to fall further as fears of restenosis diminish with
drug-eluting stents. The satisfaction with the result–often
displayed to the patient in the catheterization laboratory
by video rerun–will have a powerful therapeutic effect on
residual symptoms. The still photographs often included
in the patient chart will serve as a stimulus to clinicians for
further rapid referrals.BMC Medicine 2006, 4:25 http://www.biomedcentral.com/1741-7015/4/25
Page 4 of 12
(page number not for citation purposes)
Another not uncommon example of 'rescue' angioplasty is
the asymptomatic or minimally symptomatic patient
referred for PCI because of persistent ST-elevation of vari-
able degree, although the time window for any reasonable
expectation of myocardial salvage is well past. Poor
microvascular perfusion may well persist despite success-
ful stenting, platelet glycoprotein IIb/IIIa blockade, and
even TIMI-3 flow [32], suggesting that 'no-reflow' was the
problem in the first place and was unchanged by the inter-
vention. Inadequate myocardial perfusion despite rees-
tablished epicardial artery flow, a phenomenon that is
ischemic-time-dependent (26), in addition to a low
potential for myocardial salvage after a few hours of per-
sistent ischemia, may account for absence of consistent
and marked benefit of 'rescue' angioplasty in recent stud-
ies [33-35].
In our experience, another group frequently referred for
cardiac catheterization and PCI is post-MI patients who
perform a very adequate exercise test, indicative of low
risk, without ischemic symptoms, but whose ECG shows
ST-depression, compatible with residual myocardial
ischemia. However, several large studies, notably in the
GISSI thrombolytic cohort, have shown that the sole pres-
ence of an asymptomatic ECG-positive exercise test fol-
lowing MI predicts neither mortality nor reinfarction
[36,37]. Even the more recent DANAMI-1 study [38], with
its inherent biases in favor of aggressive intervention (sub-
optimal medical therapy and inappropriate randomiza-
tion of high-risk patients), showed only relatively small
benefit from intervention in this context [39].
The final example of overuse of invasive intervention in
STEMI is the routine recourse to angiography following
thrombolysis, resulting in anatomy-driven revasculariza-
tion of significant and, increasingly, of borderline and
noncritical lesions [40]. The belief that coronary angiogra-
phy is the most secure and definitive means of risk strati-
fication and that most of these patients will need
angiography in any case, is being espoused by growing
numbers of clinicians, contributing to the surge of PCI fol-
lowing an ACS. This strong faith in and increasing clinical
dependence on 'defining the coronary anatomy' is para-
doxical, given evidence that 1) coronary anatomy is an
unreliable indicator and predictor of symptoms, the func-
tional significance of lesions, and the risk of new or recur-
rent acute coronary instability; 2) left ventricular function
is much more prognostically important than coronary
anatomy; and 3) the prognostic capability of noninvasive
physiological stratification using the ECG exercise test or
stress nuclear perfusion imaging or echocardiography is
well established.
Older studies showing that there was no advantage to sys-
tematic invasive cardiac management after MI are consid-
ered no longer relevant in the modern era [41]. The recent
GRACIA study randomized 500 patients with acute STEMI
and concluded that a systematic invasive approach is bet-
ter than an ischemia-guided approach [42]. The primary
combined end point of death, reinfarction, and revascu-
larization at 12 months occurred in 21% of the group
whose treatment was ischemia-guided, versus 9% of the
group whose treatment was invasive (relative risk 0.44,
95% CI 0.28–0.70) and was essentially driven by the
revascularization rate. However, in a classic example of
self-fulfilling methodology, the revascularization proce-
dures that were done during the initial hospital stay did
not count in the primary end point. Had these procedures
been included in the analysis, the inference drawn from
the study would have been completely different, since
more than twice as many combined events of death, myo-
cardial infarction, and revascularization would then be
tallied in the group whose treatment was invasive as in the
group whose treatment was ischemia-guided [43].
An additional argument marshaled in support of this
approach is the open-artery hypothesis: the notion that
beyond any consideration of myocardial salvage or symp-
tomatic ischemia, there are long-term advantages to reo-
pening an occluded or severely narrowed infarct-related
coronary artery [44]. While this belief has been expressed
for over a decade, there are as yet no prospective rand-
omized trial data in its support. In fact, the only such
study found paradoxically worse left ventricular remode-
ling in patients who underwent revascularization [45].
The ongoing NIH-sponsored Open Artery Trial will help
clarify this question [46].
Thus, the previous restrained attitude that based invasive
cardiac referral after MI on well-defined high-risk clinical
criteria is being abandoned. Despite the paucity of data to
support it and with little apparent concern for its eco-
nomic and logistic implications, there are increasing calls
to recognize systematic invasive cardiac management as
the ideal option [47], one which has now become
enshrined in the latest European Society of Cardiology
guidelines on PCI as a class-1, level-of-evidence-A recom-
mendation, with the dictum that if primary PCI cannot be
performed, one should 'lyse now, stent later' [48].
Unstable angina and non-ST-elevation myocardial 
infarction (NSTEMI)
Case 3
A 49-year-old woman presented to a regional hospital with
new, constant chest pain of several hours' duration. The ECG
showed 1–2-mm inferior T-wave inversion. Treatment was ini-
tiated with nitrates, aspirin, and heparin. A few hours later,
cardiac troponin became positive and a glycoprotein IIb/IIIa
inhibitor was started as well as clopidogrel. Cardiac catheteri-
zation was requested at the nearest tertiary center, 100 milesBMC Medicine 2006, 4:25 http://www.biomedcentral.com/1741-7015/4/25
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away. The next day, with no recurrent symptoms, the patient
was transferred. Angiography showed an occluded third mar-
ginal circumflex artery, stenosis of the distal left anterior
descending artery estimated at 80%, and stenosis of the distal
right coronary artery estimated at 70%. Angioplasty was per-
formed, with insertion of two stents in the reopened marginal
artery, three stents in the left anterior descending artery, and
one stent in the distal right coronary artery. The subsequent
radiological report evaluated the pre-PCI distal left anterior
descending artery stenosis to be 40–50% and the pre-PCI distal
right stenosis to be 50%.
This case raises the questions of whether we are overtreat-
ing patients and overestimating their coronary lesion
severity.
In parallel with the preeminence achieved by interven-
tional cardiology in the management of STEMI, the pen-
dulum has now swung in favor of the invasive strategy for
patients with unstable angina and NSTEMI, much
impelled by the recent FRISC-2 and TACTICS trials
[49,50]. Earlier studies [51,52] suggesting that there is no
advantage or even that there is a worse outcome with a
systematically invasive strategy are now deemed irrele-
vant. The previous management strategy of reserving cor-
onary angiography and revascularization for patients who
were refractory to adequate medical therapy or were
hemodynamically unstable or manifested evidence of
low-threshold ischemia or signs of severe coronary artery
disease on noninvasive testing is now considered too
restrictive. What is the strength of evidence for this
change?
The FRISC-2 study [50,53] randomized 2457 patients to
either an invasive strategy with routine coronary angiogra-
phy (and revascularization depending on the coronary
artery anatomy) or initial noninvasive management. At
one year, results favored the invasively treated group both
in terms of death (2.2% versus 3.9%, p = 0.016) and death
or recurrent MI (10.4% versus 14.1%, p = 0.005). A criti-
cism of this study has been that its design disadvantaged
the initially noninvasive (or 'conservative') arm because
the clinical threshold for crossing over to the systemati-
cally invasive arm was too high. Patients had to have inca-
pacitating symptoms or do very poorly on an exercise test
(at least 3 mm ST-segment depression or limiting angina
at low workload) to qualify for crossover. This is a higher
threshold than most clinicians would normally tolerate
and may have exposed these patients to avoidable risk.
Indeed, this crossover threshold has been shown to miss
about 50% of patients with severe coronary artery disease
found by more conventional standards [54]. This finding
underscores the limitations of the term 'conservative strat-
egy', if the strategy is not anchored to clinically appropri-
ate criteria for recourse to invasive cardiac procedures.
Overly stringent criteria for crossover ensure a finding of
superiority for a systematic invasive strategy, while overly
unselective criteria lead to futile comparisons between
strategies that end up resembling each other.
The TACTICS trial [49] also concluded that an early inva-
sive strategy is superior, although the results found in this
trial are quite modest relative to the impact it has had on
the generalization of invasive cardiac management (Fig-
ure 1). The invasive strategy did not significantly reduce
mortality, and the reduction in the combined end point of
death or MI was of only borderline statistical significance
at 6 months (7.3% in the invasive arm versus 9.5% in the
conservative arm, p = 0.049). Limitations, including the
previously described detection bias for MI [55] and unbal-
ancing of adjunctive therapies following randomization
(less platelet IIb/IIIa blockade during cross-over PCI in the
conservative arm than in the invasive arm and more oral
antiplatelet therapy in the invasive arm) cloud any inter-
pretation of superiority. In support of these criticisms, the
more recent RITA 3 trial [56] found no significant differ-
ence in the occurrence of death or MI with an invasive ver-
sus a conservative approach in patients with ACS at one
year (RR 0.91; 95% CI 0.67–1.25). Only the softer end
point of 'refractory angina' was reduced with an invasive
strategy.
Notwithstanding the fragility of the above evidence in its
favor, the recently updated ACC/AHA Guidelines now call
strongly (Class I, Level of Evidence A) for an early invasive
strategy in patients with unstable angina/NSTEMI who
have any 'high-risk indicators' [57]. The need for early car-
diac catheterization with likely revascularization is undis-
puted for refractory ischemia, arrhythmic or
hemodynamic instability, ischemic heart failure, or evi-
dence of severe disease on noninvasive testing. However,
other postulated high-risk features such as PCI within 6
months or prior bypass surgery are intuitively questiona-
ble and suffer from a lack of evidence, because these
patients have often been excluded from the major clinical
trials. And while new ST-segment depression and/or
raised cardiac troponin do indicate patients at higher risk,
why is an initially conservative approach necessarily
eschewed? Most such patients in fact do well, as suggested
by the low positive predictive value (10–15%) of raised
troponin for the end point of death or MI [58]. Conse-
quently, the quasi-automatic recourse to invasive inter-
ventions and expensive drugs for all patients with ACS
and raised troponin may be questioned. It is surprising
that a major decision of clinical management now
increasingly tends to be driven by the single reading of
one blood test, without considering the patient's entire–
and dynamic–clinical picture.BMC Medicine 2006, 4:25 http://www.biomedcentral.com/1741-7015/4/25
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A very recent meta-analysis of 7 clinical trials (9212
patients) comparing routine and selective catheterization
strategies in non-ST elevation ACS actually showed signif-
icantly increased mortality during hospitalization in the
routine invasive arm and no significant overall mortality
difference (odds ratio (OR) routine versus selective 0.92;
95% CI 0.77–1.09, p = 0.33) [59]. There was an absolute
2.1% fewer nonfatal MIs (OR 0.75; 95% CI 0.65–0.88, p
< 0.001), and an absolute 2.8% less severe angina (OR
0.77; 95% CI 0.68–0.87, p < 0.001) with the routinely
invasive strategy [59]. Statistical significance notwith-
standing, these small clinical differences are further atten-
uated by the methodological limitations of TACTICS and
FRISC-2 previously discussed. Therefore, we believe the
evidence in favor of a systematic invasive strategy is not
compelling.
This position is reinforced by two very recently published
studies. The first is the long-term (3–5 years) follow-up of
the RITA 3 trial [60]. It shows a rate of death or MI of
16.6% with systematically invasive treatment and 20.0%
with conservative treatment (OR 0.78, 95% CI 0.61–0.99,
p = 0.044). Although this would seem to support a blanket
invasive approach, the small degree of benefit, an annual-
Probability density difference between invasive and conservative arms in TACTICS for combined death/MI outcome [49] Figure 1
Probability density difference between invasive and conservative arms in TACTICS for combined death/MI outcome [49]. A 
binomial model is used for the control and intervention groups, and then, because the sample sizes were large, the posterior 
distribution, which is really the difference between two beta distributions, is approximated with a normal distribution. A Hal-
dane prior (beta(0,0)), which contributes no information to the analysis, has been used. The area under the curve to the left of 
any given point represents the probability of the superiority of the invasive arm. For example, there is a 97% probability that 
the invasive arm is superior to the conservative arm (area under the curve to the left of the vertical line at 0). However, the 
probability that the benefit exceeds 1% or 2% is only 85% and 57%, respectively.BMC Medicine 2006, 4:25 http://www.biomedcentral.com/1741-7015/4/25
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ized rate difference of less than 1%, with a wide, barely
statistically significant confidence interval, suggests that
this evidence is not conclusive. Moreover, when the
patients were stratified by baseline risk, only those in the
eighth highest risk group appeared to benefit. This study
can therefore be interpreted as an incentive precisely not
to treat all patients with ACS invasively but rather to iden-
tify the minority that would truly benefit from invasive
management. The second study, the ICTUS trial [61] of
1200 troponin-positive NSTEMI patients receiving the
most contemporary medical and invasive management
strategies, found no significant difference at one year in
the combined end point of death, nonfatal MI, and rehos-
pitalization for anginal symptoms between a systematic
early invasive and a conservative strategy (1.07, 95% CI
0.87–1.33, p = 0.33). The mortality rate was the same and
MI (applying the same definition to both groups) was
actually more frequent in the group given systematically
invasive treatment (15% versus 10%, p = 0.005). These
findings were essentially unchanged when the definitions
for the MI end point of the previous studies were applied.
Cost-effective and real-world considerations
The socioeconomic aspects of the paradigm shift to sys-
tematically invasive management of ACS have been insuf-
ficiently addressed. PA is personnel-intensive, requiring
multiple teams of skilled interventional cardiologists,
nurses, radiology technicians, and physician assistants to
provide round-the-clock service. It is also resource-inten-
sive, requiring sophisticated nonreusable catheters, guide
wires, stents, and adjunctive pharmacologic therapy. In
the coming years, high-tech lassos, thrombotic aspirating
devices, and drug-eluting stents will be increasingly added
to this costly armamentarium. If patients are transferred
for PA, additional resources of ambulances and qualified
personnel will be required, often with return trips. Nor
does this approach necessarily assure an uneventful fol-
low-up. About 40% of these patients may be rehospital-
ized and about 20% may undergo a new revascularization
procedure within the year [62,63]. Although the number
of the latter will probably be reduced with the addition of
drug-eluting stents, the rate of adverse events will likely
still be about 20% [64]. Drug-eluting stents also increase
the need for long-term multiple antiplatelet drugs to pre-
vent late stent thrombosis.
Therefore, if the standard treatment of ACS is to be dis-
placed from community hospitals to become obligatorily
tertiary, the economic and logistic consequences on the
health care system and society will be appreciable [65].
The absence of discussion of these issues is paradoxical
when one considers the extensive debate that prevailed a
decade ago over a far more modest cost consideration,
namely, which of two very differently priced thrombolytic
agents should be used. For example, does a possible small
incremental benefit of PA, whose certainty may be
doubted from the preceding discussion, compared with
point-of-care thrombolysis in a patient with an uncompli-
cated acute MI justify the major additional resource costs?
As more patients undergo invasive management, the prac-
tice reinforces itself under the circular reasoning that,
since most patients will be catheterized in any case, they
should be catheterized as early as possible to derive bene-
fit quickly, nothing being gained by delay or an expectant
attitude. When comparative cost-effective analyses have
been performed, they have tended counterintuitively to
favor the invasive strategy, because the investigators have
attributed the artificially high rates of intervention
observed in their clinical trials (cardiac catheterization
rates of 63–91% and revascularization rates of 49–73%)
to the control group [49,66-69]. This is more because of
clinical practice patterns than because of clinical need, as
is attested by the marked variability of tertiary interven-
tion noted in clinical studies (less than 10% in FRISC-2,
several times more in TACTICS) [49,53], registries, and
administrative databases [70]. However, studies compar-
ing regional or national clinical practices have shown that
higher rates of invasive procedures following MI, com-
pared with much lower rates, do not improve survival,
and affect reinfarction little or not all, to justify the con-
siderable burden that generalized invasive management
entails [71-74]. Importantly, other analyses suggest that
the optimal rate of invasive intervention following MI in
terms of outcome is 20–30%, beyond which there does
not appear to be incremental benefit [75,76].
It is underappreciated that very recent and large registry
studies actually lend support to a more selective rather
than routine invasive approach in the management of
acute coronary disease. GRACE, a prospective multina-
tional observational registry study involving 28,825
patients with ACS, showed higher adjusted risks of death,
stroke, and bleeding complications at 6 months in
patients first admitted to hospitals with catheterization
facilities than to hospitals without them, despite 10 times
more revascularization procedures in the former hospitals
(41% versus 3.9% for PCI and 7.1% versus 0.7% for coro-
nary bypass surgery, respectively) [77]. This study calls
into question the increasingly advocated notion that
patients with ACS should be directed preferentially to ter-
tiary centers for routine invasive treatment. In similar
vein, a cohort study of 158,831 elderly Medicare patients
hospitalized with acute MI and followed for 7 years found
that routine use of more costly and invasive treatment
strategies was not associated with a benefit beyond that
seen with excellent medical management [78].
It is argued that expeditious invasive management of
patients with ACS shortens hospital stays, rendering thisBMC Medicine 2006, 4:25 http://www.biomedcentral.com/1741-7015/4/25
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approach cost-effective. According to this perspective, the
problem is essentially the 'culprit lesion' and once it has
been rapidly 'fixed', early discharge makes this approach
superior to the more protracted scenario of medical stabi-
lization, 'watchful waiting', and non-invasive stratifica-
tion. However, algorithms shortening hospital stays with
noninvasive approaches have been validated, although
they receive less attention [79]. Studies that show reduced
hospital stays with invasive management are necessarily
unblinded, with possible introduction of bias.
Philosophical and broader implications
The increased recourse to invasive management of acute
coronary disease also raises provocative philosophical,
intellectual, and social issues. First, there is a tendency to
reduce acute coronary disease, and atherosclerosis in gen-
eral, to the problem of a defective localized segment of a
coronary conduit amenable to an expeditious mechanical
fix. This perception is paradoxical given the growing
understanding of the diffuse and inflammatory nature of
the atherosclerotic disease process and the complex biol-
ogy of the vascular wall, including recent data suggesting
the simultaneous presence of multiple potential culprit
plaques in acute coronary disease [80,81]. The current ten-
dency to dilate coronary stenoses solely on the basis of
their perceived severity (the so-called oculo-stenotic
reflex) also disregards sound evidence that coronary
lesions that are the substrate for ACS are quite often not
severely stenosed, whereas some severe stenoses are
known to remain stable for many years [82-85]. The
reductionist perception also has far-reaching conse-
quences for the quality of the patient-physician relation-
ship, academic medicine, and patient and public
comprehension of a very serious disease ('They unblocked
my artery!'). Nor may it render a service to the patient in
terms of adequately addressing the hardly negligible psy-
chological dimension and the importance of organizing
an effective and empowering strategy of prevention.
A second issue is the fundamental terminological trap
inherent in the 'aggressive' versus 'conservative' debate on
the management of acute coronary disease. When the
medical problem is perceived as serious and high-risk,
'conservative' bears the stigmatism of being passé, convey-
ing a sense of defeatism, grudging parsimony, doing less
than the maximum best for the patient. If the 'conserva-
tive' approach fails, it confirms that the clinician was too
passive and must assume the opprobrium, indeed may
risk a lawsuit. 'Aggressive' implies courage and active will
to engage an enemy disease, and enjoys the aura of power
and high-tech glamor. If the intervention fails or provokes
unfortunate side effects, blame is unlikely to accrue to the
chooser of the aggressive course, vindicated because the
problem was indeed serious, as events bore out, and all
was done that could have been done. We must be aware
how language and the unconscious cultural images it
evokes condition our perceptions of patient management
and the values we transmit to trainees, colleagues,
patients, and the general public.
A third issue is the acceptance of a therapeutic attitude
that justifies complex tertiary care intervention for a com-
mon medical condition for at most marginal clinical ben-
efit. If it is granted–although we have argued this is
debatable–that recourse to generalized invasive cardiac
procedures leads to some meaningful health benefits,
does it follow that we must accept the imposition of an
enormous therapeutic burden on all because we are una-
ble to use clinical judgment to identify more narrowly
those most likely to benefit? Maseri has likened this prob-
lem to a hypothetical scenario where we would treat all
patients who have anemia with iron or vitamin supple-
ments [86]. While there would likely be a statistically sig-
nificant benefit from such an intervention, this would be
regarded as inappropriate clinical practice, because it dis-
regards the notion that anemia may have many causes.
Unselective, expensive treatments in acute coronary dis-
ease are not presently perceived as an imperfect approach
and an implicit admission of clinical impotence [87].
Fourthly, generalized tertiary management of acute coro-
nary disease has consequences for fragile health care sys-
tems and society. Where these resources are rarer, ready
access for those especially in need of tertiary cardiac care
risks being compromised because the queue has become
too long and unselective. Necessary care for the less fortu-
nate may be particularly jeopardized. The strain placed on
already beleaguered universal health care systems may
menace their integrity besides adversely affecting other
health care domains and societal priorities [88].
Fifthly, interventional cardiology is highly remunerative
in most medical systems based on fee for service, and ter-
tiary cardiac centers clearly benefit from the contemporary
approach to ACS. It has increasingly become the clinical
practice that the diagnostic angiogram, the decision to do
PCI, and the procedure itself are performed in the same
session by the same individuals (judge, jury, and execu-
tioner?), creating a situation less propitious for consider-
ing other options such as simple abstention or recourse to
cardiac surgery that have more clinical benefit in certain
situations [89]. The direct and indirect conflicts of interest
inherent in this situation and the manner in which this
may affect how study findings have been interpreted and
applied in clinical practice have generally been insuffi-
ciently acknowledged and ventilated. This problem is
compounded by the increasing involvement of the car-
diac-device industry in clinical studies and the multiple
roles assumed by the same individuals as principal inves-BMC Medicine 2006, 4:25 http://www.biomedcentral.com/1741-7015/4/25
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tigators, consultants, authors, opinion-leaders, and mem-
bers of guidelines committees.
And finally, the invasively based homogenization of cur-
rent medical practice in acute coronary disease and the
pressures to conform that it has induced are abolishing
the intellectual space that is normally occupied–and
savored–by discriminating clinical judgment. Acute coro-
nary care is at risk of becoming a far less attractive field to
those seeking creative challenges as clinicians and stu-
dents of pathophysiology. And if ACS becomes a tertiary
disease, will recruitment of cardiovascular specialists to
secondary hospitals not risk being jeopardized? Might this
development not ultimately result in suboptimal treat-
ment of cardiovascular disease in nontertiary settings [65]
? Moreover, questions about the continuity of care follow-
ing the acute coronary episode have not been adequately
addressed.
Summary
In its relatively unselective plunge into technology, we
believe contemporary cardiology has taken a turn that is
problematic, on scientific, economic, and intellectual
grounds. The capital notion that diagnostic procedures
and treatments should be adapted to patients–and not
patients to treatments–with their unique clinical particu-
larities, differing underlying pathogenic mechanisms, and
heterogeneous risk profiles, should not fall victim to a sys-
tematic steamroller approach in patients with ACS. We
dare hope that the countervailing attitude expressed here
may contribute to the salutary debate necessary for an
equilibrium in which clinical finesse and discriminating
judgment may assume their proper place in the manage-
ment of patients with acute ischemic heart disease.
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